BCYC - Bicycle Therapeutics PLC Market Cap to Sales Volume

Corporate company logo of Bicycle Pharma (BCYC)

Bicycle Therapeutics (BCYC) derives its uniqueness from synthetic peptides designed for targeted drug delivery. The price-to-sales multiple visualizes the asset's market valuation, where 2.10 determines the current status of the parameter. Growth is driven by strategic alliances with pharmaceutical behemoths, although logistics in the US and EU could be complicated by geopolitical tensions and patent disputes.

Bicycle Pharma (BCYC) - Price-to-Revenue Ratio from 07/04/2022 to 11/14/2026

Metric breakdowns and analytics for Bicycle Pharma (BCYC)

- stock value and consensus price forecast:
Stock Price bicycletherapeutics.com|BCYC - Consensus Target
- market capitalization statistics:
Market Value Bicycle Pharma|BCYC - Enterprise Value
- book capitalization information:
Share Book Value Bicycle Therapeutics|BCYC - Company Book Value|Market-to-Book Ratio bicycletherapeutics.com|BCYC - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Bicycle Therapeutics|BCYC - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Bicycle Corp|BCYC - Company Debts|Debts to Net Assets Bicycle Pharma|BCYC - Company Long-Term Debts|Company Short-Term Debt Bicycle Therapeutics|Interim Coverage Ratio bicycletherapeutics.com
- earnings and valuation multiples indicators:
BCYC - Net Profit|Future Profit Bicycle Therapeutics|BCYC - Price to Earnings Ratio|Projected Price to Earnings Ratio Bicycle Therapeutics PLC|BCYC - PEG Multiple|Enterprise Value to EBITDA Ratio Bicycle Pharma|BCYC - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Bicycle Therapeutics|BCYC - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months bicycletherapeutics.com|BCYC - Net earnings per share growth this year|Expected earnings per share trend next year Bicycle Therapeutics
- total revenue and sales volume data:
BCYC - Company Sales|Company Projected Revenue Volume bicycletherapeutics.com|BCYC - P/S Multiple|Forward Price to Sales Bicycle Pharma
Fundamental company analysis:BCYC, bicycletherapeutics.com
Finished products of Bicycle Therapeutics

To assess the valuation of Bicycle Therapeutics (BCYC), which develops innovative peptide cancer drugs, tracking the company's price-to-sales ratio is critical. This indicator is calculated by dividing the market capitalization by annual sales, allowing investors to analyze the chart to determine whether assets are overvalued or to identify unjustified speculative growth amid the development of new therapies.

Competing companies

P/S Multiple geron.com (GERN)|Nanobiotix - Market Cap to Revenue|Market Cap to Sales Volume CTMX (CytomX Pharma)|Perspective Therapeutics Inc - P/S Multiple|Price-to-Sales Ratio GNLX|Molecular Partners AG (MOLN) - Price-to-Revenue Ratio|Price to Sales Oncolytics Biotech (ONCY)|Price-to-Revenue Ratio Lisata Therapeutics Inc.|MBRX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Galera Therapeutics (GRTX)|Market Cap to Revenue Molecular Templates Corporation MTEM